Effects of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in patients with acute respiratory failure.

Effects of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in patients with acute respiratory failure. - Dexmedetomidine for sleep disturbance and delirium during high flow oxygen therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015650

Enrollment

Registered

2015-02-01

Start date

2015-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with acute respiratory failure treated with high flow oxygen therapy

Interventions

Dexmedetomidine 0.2-0.7mcg/kg/h for nocturnal sedation No sedation or sedation without dexmedetomidine during night time.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with acute respiratory failure equipped with high flow oxygen therapy in the intensive care units.

Exclusion criteria

Exclusion criteria: Major cardiovascular disease, shock, cerebrovascular disease, known sleep apnea syndrome, mental disorder.

Design outcomes

Primary

Measure	Time frame
Sleep quality and quantity (total sleep time, the rate of each sleep stage: non-REM sleep stage 1-3, REM sleep) and the incidence rate of delirium.	—

Secondary

Measure	Time frame
successful rate of liberation from high flow oxygen therapy, the length of ICU stay, and mortality.	—

Countries

Japan

Contacts

Public ContactJun Oto

Tokushima University Hospital Emergency and Critical Care Medicine

joto@tokushima-u.ac.jp088-633-9347

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026